索磷布韦维帕他韦治疗慢性丙型肝炎肝纤维化的疗效及对肝功能、血清细胞因子的影响研究  

Study on the Efficacy of Sofosbuvir and Velpatasvir in the Treatment of Chronic Hepatitis C Liver Fibrosis and Its Influence on Liver Function and Serum Cytokines

作　　者：陈晖蓉 魏伯栋 宋佳音 王娟娟 CHEN Huirong;WEI Bodong;SONG Jiayin;WANG Juanjuan(Infection Department,Zhangye People's Hospital Affiliated to Hexi University,Zhangye 734000,Gansu,China;School of Life Science and Engineering,Hexi University,Zhangye 734000,Gansu,China)

机构地区：[1]河西学院附属张掖人民医院感染科,甘肃张掖734000 [2]河西学院生命科学与工程学院,甘肃张掖734000

出　　处：《中外医疗》2024年第20期9-12,共4页China & Foreign Medical Treatment

摘　　要：目的分析慢性丙型肝炎(Chronic Hepatitis C,CHC)肝纤维化治疗中索磷布韦维帕他韦对肝功能、血清细胞因子的影响。方法方便选取2020年1月—2022年12月河西学院附属张掖人民医院就诊的162例CHC肝纤维化患者为研究对象,根据随机数表法分为两组,每组81例,常规组给予利巴韦林等常规治疗,观察组在常规组基础上给予索磷布韦维帕他韦治疗,比较两组患者临床疗效、肝功能指标[总胆红素(Total Bilirubin,TBIL)、丙氨酸氨基转移酶(Alanine Aminotransferase,ALT)]、肝纤维化指标[透明质酸(Hyaluronic Acid,HA)、层连蛋白(Laminin,LN)]、血清细胞因子[肿瘤坏死因子-α(Tumor Necrosis Factor-α,TNF-α)、白细胞介素-6(Interleukin-6,IL-6)]、不良反应总发生率。结果观察组临床总有效率(96.30%)高于常规组(81.48%),差异有统计学意义(χ^(2)=9.000,P=0.003)。治疗后,观察组TBIL、ALT均低于常规组,差异有统计学意义(P均<0.05)。治疗后,观察组HA、LN均低于常规组,差异有统计学意义(P均<0.05)。治疗后,观察组血清TNF-α、IL-6水平均低于常规组,差异有统计学意义(P均<0.05)。观察组不良反应总发生率(4.94%)与常规组(6.17%)比较,差异无统计学意义(χ^(2)=0.118,P=0.732)。结论索磷布韦维帕他韦可有效改善CHC肝纤维化患者肝功能及肝纤维化,降低血清炎症因子水平,且未增加不良反应发生率,临床治疗安全有效。Objective To analyze the effects of sofosbuvir and velpatasviron liver function and serum cytokines during chronic hepatitis C(CHC)liver fibrosis treatment.Methods 162 patients with CHC liver fibrosis treated in Zhangye People's Hospital Affiliated to Hexi University from January 2020 to December 2022 were conveniently selected as the study objects,and were divided into two groups according to the random number table method,with 81 cases in each group.The conventional group was given routine treatment such as ribavirin,while the observation group was given sofosbuvir and velpatasvir treatment on the basis of conventional group.The clinical efficacy,liver function indicators[total bilirubin(TBIL),alanine aminotransferase(ALT)],and liver fibrosis indicators[hyaluronic acid(HA),laminin(LN)],serum cytokines[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)]and the overall incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group(96.30%)was higher than that of the conventional group(81.48%),and the difference was statistically significant(χ^(2)=9.000,P=0.003).After treatment,TBIL and ALT in the observation group were lower than those in the conventional group,and the differences were statistically significant(both P<0.05).After treatment,HA and LN in observation group were lower than those in conventional group,and the differences were statistically significant(both P<0.05).After treatment,the serum levels of TNF-αand IL-6 in observation group were lower than those in conventional group,and the differences were statistically significant(both P<0.05).There was no significant difference in the total incidence of adverse reactions between the observation group(4.94%)and the conventional group(6.17%)(χ^(2)=0.118,P=0.732).Conclusion Sofosbuvir can effectively improve liver function and liver fibrosis in CHC patients with liver fibrosis,reduce the level of serum inflammatory factors,and do not increase the incidence of adverse reactions.The clinical t

关 键 词：索磷布韦维帕他韦 慢性丙型肝炎 肝纤维化 肝功能 

分 类 号：R5[医药卫生—内科学]